Doxorubicin cardiotoxicity and target cells: a broader perspective

The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication makes difficult to design successful preventive or curative measures. Although cardiomyocyte has been considered a classical cellular target, other cells including various types of undifferentiated cells are involved in myocardial homeostasis. Such perspective may shed light on previously unrecognized aspects of cardiotoxicity and promote new experimental and clinical cardioprotective strategies. In this review, different cellular targets of doxorubicin are discussed with the focus on cardiac progenitor cells, oxidative stress, DNA damage, senescence and apoptosis all of which contribute to their compromised functional properties.

• Publication year

  2016

• Venue

  Cardio-Oncology

• Publication date

  2016-03-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s40959-016-0012-4PMID 33530140PMCID 7837148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy.

  2016cited by this paper
• SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells.

  2015cited by this paper
• Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

  2015cited by this paper
• The concomitant management of cancer therapy and cardiac therapy.

  2015cited by this paper
• Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size and Enhances Angiogenesis

  2015cited by this paper
• Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications

  2015cited by this paper
• Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

  2015cited by this paper
• Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells.

  2015cited by this paper
• Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.

  2015cited by this paper
• Comparison of Different Bone Marrow-Derived Stem Cell Approaches in Reperfused STEMI. A Multicenter, Prospective, Randomized, Open-Labeled TECAM Trial.

  2015cited by this paper
• Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors.

  2015cited by this paper
• Report on the International Colloquium on Cardio-Oncology (Rome, 12–14 March 2014)

  2014cited by this paper
• Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence

  2014cited by this paper
• Doxorubicin has in vivo toxicological effects on ex vivo cultured mesenchymal stem cells.

  2014influential reference
• Dynamic Changes in Myocardial Matrix and Relevance to Disease: Translational Perspectives

  2014cited by this paper
• Interaction between myofibroblasts and stem cells in the fibrotic heart: balancing between deterioration and regeneration.

  2014cited by this paper
• Rationale and Design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study)

  2014cited by this paper
• Ex Vivo Molecular Rejuvenation Improves the Therapeutic Activity of Senescent Human Cardiac Stem Cells in a Mouse Model of Myocardial Infarction

  2014cited by this paper
• Ranolazine in the prevention of anthracycline cardiotoxicity.

  2014cited by this paper
• Cancer treatment and survivorship statistics, 2014

  2014cited by this paper
• A comparison of replicative senescence and doxorubicin-induced premature senescence of vascular smooth muscle cells isolated from human aorta

  2013cited by this paper
• Doxorubicin Caused Apoptosis of Mesenchymal Stem Cells via p38, JNK and p53 Pathway

  2013influential reference
• Doxorubicin induces senescence and impairs function of human cardiac progenitor cells

  2013influential reference
• Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.

  2013cited by this paper
• Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.

  2013cited by this paper
• Granulocyte colony stimulating factor therapy for acute myocardial infarction.

  2013cited by this paper
• Pressure overload leads to an increase of cardiac resident stem cells

  2012cited by this paper
• Metabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms

  2012cited by this paper
• Anthracycline cardiotoxicity

  2012cited by this paper
• Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

  2012cited by this paper
• Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.

  2012cited by this paper
• Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.

  2012cited by this paper
• Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

  2011cited by this paper
• The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

  2011cited by this paper
• Effects of age and heart failure on human cardiac stem cell function.

  2011cited by this paper
• Insulin-Like Growth Factor-1 Receptor Identifies a Pool of Human Cardiac Stem Cells With Superior Therapeutic Potential for Myocardial Regeneration

  2011cited by this paper
• Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.

  2011cited by this paper
• The use of liposomal anthracycline analogues for childhood malignancies: A systematic review.

  2011cited by this paper
• Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease?

  2010cited by this paper
• Myocyte Turnover in the Aging Human Heart

  2010cited by this paper
• Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair.

  2010cited by this paper
• Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

  2010cited by this paper
• Making cellular memories.

  2010cited by this paper
• Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

  2010cited by this paper
• Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice

  2010cited by this paper
• Sublethal Doses of an Anti-erbB2 Antibody Leads to Death by Apoptosis in Cardiomyocytes Sensitized by Low Prosenescent Doses of Epirubicin: The Protective Role of Dexrazoxane

  2010cited by this paper
• p38 MAPK and JNK Antagonistically Control Senescence and Cytoplasmic p16INK4A Expression in Doxorubicin-Treated Endothelial Progenitor Cells

  2010cited by this paper
• Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function

  2010cited by this paper
• Granulocyte colony‐stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single‐blind, randomized, placebo‐controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM‐AMI) Trial

  2010cited by this paper
• Human cardiac stem cells: the heart of a truth.

  2009cited by this paper
• New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.

  2008cited by this paper
• Antagonistic control of cell fates by JNK and p38-MAPK signaling

  2008cited by this paper
• Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage

  2008cited by this paper
• Activation of Cardiac Progenitor Cells Reverses the Failing Heart Senescent Phenotype and Prolongs Lifespan

  2008cited by this paper
• Anthracycline cardiotoxicity: from bench to bedside.

  2008cited by this paper
• Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy

  2008cited by this paper
• Cardiac safety of liposomal anthracyclines

  2007cited by this paper
• Human cardiac stem cells

  2007cited by this paper
• Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens

  2007cited by this paper
• Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.

  2007cited by this paper
• Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.

  2007cited by this paper
• Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

  2006cited by this paper
• Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.

  2006cited by this paper
• Diabetes Promotes Cardiac Stem Cell Aging and Heart Failure, Which Are Prevented by Deletion of the p66shc Gene

  2006cited by this paper
• Anthracycline cardiotoxicity

  2006cited by this paper
• Stem cell niches in the adult mouse heart.

  2006cited by this paper
• Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

  2006cited by this paper
• Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function.

  2005cited by this paper
• Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

  2005cited by this paper
• Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure.

  2005cited by this paper
• Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans

  2005cited by this paper
• CD31− but Not CD31+ Cardiac Side Population Cells Exhibit Functional Cardiomyogenic Differentiation

  2005cited by this paper
• Cardiac Stem Cells Possess Growth Factor-Receptor Systems That After Activation Regenerate the Infarcted Myocardium, Improving Ventricular Function and Long-Term Survival

  2005cited by this paper
• Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors.

  2005cited by this paper
• Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy.

  2004cited by this paper
• Cardiac Stem Cell and Myocyte Aging, Heart Failure, and Insulin-Like Growth Factor-1 Overexpression

  2004cited by this paper
• Endothelial Progenitor Cells: Characterization and Role in Vascular Biology

  2004cited by this paper
• Regeneration of heart muscle tissue: quantification of chimeric cardiomyocytes and endothelial cells following transplantation.

  2004cited by this paper
• Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis.

  2004cited by this paper
• Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.

  2004cited by this paper
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  2004cited by this paper
• Antioxidants and cancer therapy: a systematic review.

  2004cited by this paper
• High Intensity ras Signaling Induces Premature Senescence by Activating p38 Pathway in Primary Human Fibroblasts*

  2004cited by this paper
• Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

  2003cited by this paper
• Circulating endothelial progenitor cells, vascular function, and cardiovascular risk.

  2003cited by this paper
• DNA damage foci at dysfunctional telomeres.

  2003cited by this paper
• G-CSF Promoted Bone Marrow Cells to Migrate into Infarcted Heart and Differentiate into Cardiomyocytes

  2003cited by this paper
• Reversal of human cellular senescence: roles of the p53 and p16 pathways

  2003cited by this paper
• Senescence and Death of Primitive Cells and Myocytes Lead to Premature Cardiac Aging and Heart Failure

  2003cited by this paper
• Cardiac safety of liposomal anthracyclines.

  2003cited by this paper
• Adult cardiac stem cells are multipotent and support myocardial regeneration.

  2003cited by this paper
• Chimerism of the transplanted heart.

  2002cited by this paper
• Chimerism of the transplanted heart.

  2002cited by this paper
• Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1

  2001cited by this paper
• Chronic vascular toxicity of doxorubicin in an organ‐cultured artery

  2001cited by this paper
• Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon.

  2001cited by this paper
• Adriamycin-induced heart failure: mechanisms and modulation

  2000cited by this paper
• Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

  2000cited by this paper
• Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization

  1999cited by this paper
• Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon

  1999cited by this paper

• PTUPB, a soluble epoxide hydrolase/cyclooxygenase-2 dual inhibitor, reduces endothelial-to-mesenchymal transition and improves doxorubicin-induced vascular and cardiac toxicity

  2026cites this paper
• Cannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway

  2025cites this paper
• AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage

  2025cites this paper
• Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells

  2025cites this paper
• Cell-Permeable Microprotein from Panax Ginseng Protects Against Doxorubicin-Induced Oxidative Stress and Cardiotoxicity

  2025cites this paper
• Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center

  2025cites this paper
• Activation of CISD2 as a protective strategy against doxorubicin-induced cardiotoxicity

  2025cites this paper
• Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity

  2025influential citation
• Role of biocompatible PMMA-PEG@Ag nanocomposite in the specific delivery of doxorubicin and resveratrol

  2025cites this paper
• Anti-Müllerian Hormone Ameliorates Uterine DNA Damage Response and Prevents Pregnancy Complications in Doxorubicin-Treated Mice†.

  2025cites this paper
• NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity

  2025cites this paper
• The Effect of Quercetin on Radiosensitivity and the Adaptive Response in Mice

  2025cites this paper
• A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging

  2024cites this paper
• Inhibition of cytochrome P450 epoxygenase promotes endothelium-to-mesenchymal transition and exacerbates doxorubicin-induced cardiovascular toxicity

  2024cites this paper
• Anthracycline-Induced Cardiomyopathy in Cancer Survivors: Management and Long-Term Implications.

  2024cites this paper
• AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage

  2024cites this paper
• Inhibition of TBL1 cleavage alleviates doxorubicin-induced cardiomyocytes death by regulating the Wnt/β-catenin signal pathway

  2024cites this paper
• Addressing Cardiovascular Toxicity Risk of Electronic Nicotine Delivery Systems in the Twenty-First Century: “What Are the Tools Needed for the Job?” and “Do We Have Them?”

  2024cites this paper
• EARLY MARKERS OF ACUTE DOXORUBICIN-INDUCED CARDIOTOXICITY AND MECHANISMS OF ITS DEVELOPMENT

  2024cites this paper
• Effects of doxorubicin on autophagy in fibroblasts

  2024cites this paper
• Senolytics rejuvenate aging cardiomyopathy in human cardiac organoids.

  2024cites this paper
• Doxorubicin Incorporation into Gold Nanoparticles: An In Vivo Study of Its Effects on Cardiac Tissue in Rats

  2024cites this paper
• Doxorubicin-induced modulation of TGF-β signaling cascade in mouse fibroblasts: insights into cardiotoxicity mechanisms

  2023cites this paper
• Initial Phase of Anthracycline Cardiotoxicity Involves Cardiac Fibroblasts Activation and Metabolic Switch

  2023cites this paper
• Effects of Doxorubicin on Extracellular Matrix Regulation in Primary Cardiac Fibroblasts from Mice

  2023cites this paper
• Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway.

  2023cites this paper
• In vitro evaluation and in vivo efficacy studies of a liposomal doxorubicin-loaded glycyrretinic acid formulation for the treatment of hepatocellular carcinoma

  2023cites this paper
• The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats

  2022cites this paper
• The Innate Immune System in Cardiovascular Diseases and Its Role in Doxorubicin-Induced Cardiotoxicity

  2022cites this paper
• Cardiac Remodelling Following Cancer Therapy: A Review

  2022cites this paper
• Anthracycline-induced cardiotoxicity and senescence

  2022cites this paper
• Dihydromyricetin protects against Doxorubicin-induced cardiotoxicity through activation of AMPK/mTOR pathway.

  2022cites this paper
• Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

  2022cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey

  2021cites this paper
• An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.

  2021cites this paper
• Small extracellular vesicles in cancer

  2021cites this paper
• Senescence mechanisms and targets in the heart.

  2021cites this paper
• Treatment Of Albino Rats With Oltipraz (4-MethyL-5-PyrazinyL-3H-1,2-Dithiole-3-Thione Protects Against Doxorubicin-Induced Cardiotoxicity

  2021cites this paper
• Functionalization of Polyethyleneimine with Hollow Cyclotriveratrylene and Its Subsequent Supramolecular Interaction with Doxorubicin

  2020cites this paper
• Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods

  2020cites this paper
• Mahonia aquifolium Extracts Promote Doxorubicin Effects against Lung Adenocarcinoma Cells In Vitro

  2020cites this paper
• The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity

  2020cites this paper
• Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity

  2020cites this paper
• A short review: Doxorubicin and its effect on cardiac proteins

  2020cites this paper
• Cytoprotective and antioxidant effects of aged garlic extract against adriamycin-induced cardiotoxicity in adult male rats

  2020cites this paper
• Chapter 2 Doxorubicin Cardiotoxicity : Multiple Targets and Translational Perspectives

  2019cites this paper
• Biocompatible Chitosan Nanobubbles for Ultrasound-Mediated Targeted Delivery of Doxorubicin

  2019cites this paper
• Irbesartan suppresses cardiac toxicity induced by doxorubicin via regulating the p38-MAPK/NF-κB and TGF-β1 pathways

  2019cites this paper
• Micheliolide Protects Against Doxorubicin-Induced Cardiotoxicity in Mice by Regulating PI3K/Akt/NF-kB Signaling Pathway

  2019cites this paper
• Effects of high-intensity interval training on the expression of microRNA-499 and pro- and anti-apoptotic genes in doxorubicin-cardiotoxicity in rats.

  2019cites this paper
• CORRECTIVE ACTION OF CERIUM DIOXIDE NANOPARTICLES IN THE CONDITIONS OF OXIDATIVE STRESS INPUT OF DOXORUBICIN-INDUCED CARDIOMYOPATHY IN RATS

  2019cites this paper
• Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment

  2019cites this paper
• Disruption of mitochondrial membrane potential coupled with alterations in cardiac biomarker expression as early cardiotoxic signatures in human ES cell–derived cardiac cells

  2019cites this paper
• Patterns of comorbidities in women with breast cancer: a Canadian population-based study

  2019cites this paper
• Cardio-protective Effect of Vitamin E on Doxorubicin-Induced Cardiotoxicity in Adult Male Albino Rats: A Histological and Biochemical Study

  2019cites this paper
• Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

  2019cites this paper
• Epigenetic Targets in Synovial Sarcoma: A Mini-Review

  2019cites this paper
• Microgravity Modulates Effects of Chemotherapeutic Drugs on Cancer Cell Migration

  2019cites this paper
• Assessment of Tiron as a cardioprotective agent

  2019cites this paper
• Macrophage‐Mediated Delivery of Hypoxia‐Activated Prodrug Nanoparticles

  2019cites this paper
• Amphiphilic polymers as enhanced drug delivery systems

  2018cites this paper
• Doxorubicin Cardiotoxicity: Multiple Targets and Translational Perspectives

  2018cites this paper
• The potential toxic effects of chronic doxorubicin treatment on the rat pancreas and the role of ghrelin in this context

  2018cites this paper
• Aerobic Exercise for Optimizing Cardiopulmonary Fitness in Childhood Cancer Survivors Treated with a Known Cardiotoxic Agent: A Meta-Analysis

  2018cites this paper
• Fluorescence intensity modulation of CdSe/ZnS quantum dots assesses reactive oxygen species during chemotherapy and radiotherapy for cancer cells

  2018cites this paper
• Electroneutral polymersomes for combined cancer chemotherapy.

  2018cites this paper
• ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells1

  2018cites this paper
• Molecular mechanism of doxorubicin‐induced cardiomyopathy – An update

  2018cites this paper
• Doxorubicin targets multiple players: A new view of an old problem

  2018cites this paper
• Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity

  2018cites this paper
• Imatinib mesylate‐induced cardiomyopathy involves resident cardiac progenitors

  2018cites this paper
• Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model

  2018cites this paper
• Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.

  2018cites this paper
• The Static Magnetic Field Remotely Boosts the Efficiency of Doxorubicin through Modulating ROS Behaviors

  2018cites this paper
• Cardiotoxicity of Anticancer Therapeutics

  2018cites this paper
• 3, 4, 10-Trimethoxystilbene Suppresses Human Hepatocellular Carcinoma Cell Proliferation

  2017cites this paper
• Controlled release of nitric oxide from liposomes.

  2017cites this paper
• Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer

  2017cites this paper
• Anticancer potency of nitric oxide-releasing liposomes.

  2017cites this paper
• Role of Cardiac Imaging in Cardiovascular Diseases in Females

  2017cites this paper
• Functional and Structural Assessment of the Effect of Human Umbilical Cord Blood Mesenchymal Stem Cells in Doxorubicin‐Induced Cardiotoxicity

  2017cites this paper
• Protein Corona around Gold Nanorods as a Drug Carrier for Multimodal Cancer Therapy.

  2017cites this paper
• Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells

  2017cites this paper
• A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity

  2016cites this paper
• Chemotherapy impedes in vitro microcirculation and promotes migration of leukemic cells with impact on metastasis.

  2016cites this paper
• Doxorubicin-induced chronic dilated cardiomyopathy—the apoptosis hypothesis revisited

  2016influential citation
• Central Lancashire Online Knowledge (CLoK)

  year unknowncites this paper